Innovation Pharmaceuticals Inc (IPIX)

[To infinity and beyond!]

The real DD we need: get into the Letai lab at Dana Farber with APR-246 and K for a comparison with the new tool BDG. This assumes BDG really works, and that there is a known K dose to compare.

here is the problem.

K will not be first in class. PiSARRO, the APR-246 study with ovarian CA is already farther along, and if safety is ok and the drug works with the trial combo it will beat K to market.

That of course does not matter at all if K works better than APR-246.